To confirm tau vs. tau & Aβ driven changes in late-stage AD brain myeloid cells, we compared pseudobulk gene expression in high-tau/low Aβ vs. low-tau/low-Aβ (EC vs. V1, tau-driven), high-tau/high-Aβ vs. high-tau/low-Aβ (PFC vs. EC, Aβ-driven), and high-tau/high-Aβ vs. low-tau/low-Aβ (PFC vs. V1, tau & Aβ-driven) regions within high pathology group 4 donors, controlling for regional changes observed in low-pathology group 1 donors (Fig. 5a, Table S12). The gene discussed is MAPT; the disease is Alzheimer disease.